Understanding the genetic causes of prostate cancer
Elucidation of the genetic mechanisms driving prostate tumorigenesis through integrative computational and functional approaches
This study is looking at how our genes might affect the risk of getting prostate cancer, with the hope of finding new ways to treat it that are better suited to each person's unique genetic makeup.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11061345 on NIH RePORTER |
What this research studies
This research investigates the genetic factors that contribute to prostate cancer by analyzing large datasets from genome-wide association studies. It aims to uncover the mechanisms linking genetic variations to the risk of developing prostate cancer, which could lead to new drug targets and personalized treatment options. By integrating various types of biological data, including gene expression and epigenetic modifications, the study seeks to identify and validate specific genes and variants that play a role in the disease. Patients may benefit from insights that could improve treatment strategies tailored to their genetic profiles.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk for prostate cancer, particularly those with a family history or genetic predispositions.
Not a fit: Patients with prostate cancer that is not influenced by genetic factors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for prostate cancer patients.
How similar studies have performed: Previous research has shown promise in using big data approaches to uncover genetic mechanisms in various cancers, suggesting a potential for success in this area as well.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Freedman, Matthew L — Dana-Farber Cancer Inst
- Study coordinator: Freedman, Matthew L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.